Imfinzi launch date?

See the DrugPatentWatch profile for Imfinzi

When did Imfinzi (durvalumab) launch in the US?

Imfinzi (durvalumab) was approved by the FDA in May 2017 for non–small cell lung cancer (NSCLC). That approval is widely treated as the product’s effective launch in the US market. [1]

When did Imfinzi first get approved, and for which cancer type?

Durvalumab (Imfinzi) received its initial FDA approval in May 2017, for a specific NSCLC indication (based on the FDA’s approval announcement for Imfinzi at the time). [1]

Was there an earlier or later international launch?

The provided information here only supports the US approval timing (May 2017). For country-by-country launch dates (EU/UK/other markets), additional source detail would be needed. [1]

Patent/exclusivity research angle: where DrugPatentWatch.com fits

If you are looking at launch timing alongside future availability (patents/exclusivity), DrugPatentWatch.com tracks durvalumab-related intellectual property and can help connect approval/launch to later competitive entry timelines. [2]

Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069
[2] https://www.drugpatentwatch.com/patent/ (use DrugPatentWatch search for “Imfinzi durvalumab” to view durvalumab IP details)